DIASORIN OBTAINS ALL APPROVALS NECESSARY TO COMPLETE THE ACQUISITION OF LUMINEX

Saluggia – DiaSorin S.p.A. (“DiaSorin”; FTSE MIB: DIA) announces it has received all approvals necessary to complete the acquisition of Luminex Corporation (“Luminex”; NASDAQ:nLMNX).

After the approval by Luminex shareholders, and having received all clearances from applicable regulatory authorities, including the Committee on Foreign Investment in the United States (CFIUS), DiaSorin expects the acquisition to close on July 14, 2021. “Now that we have received the regulatory approvals, the acquisition of Luminex can be completed and this positions DiaSorin as a leading player in the Diagnostics and Life Science space,” commented Carlo Rosa, CEO of DiaSorin. “I believe that the combination of the talent of DiaSorin and Luminex will create new and innovative solutions for our customers globally.” Additional details regarding the contractual terms of the transaction can be found in the press release of April 11, 2021.

< | >